GLS

Gelesis Holdings, Inc. [GLS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GLS Stock Summary

In the News

GLS Financial details

Company Rating
-
Market Cap
11.63M
Income
-50.39M
Revenue
12.14M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
93
Optionable
No
Shortable
Yes
Earnings
14 Aug 2023
P/E
-0.21
Forward P/E
-
PEG
0.02
P/S
0.58
P/B
-0.44
P/C
-
P/FCF
-0.2
Quick Ratio
0.35
Current Ratio
0.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.69
EPS next Y
-
EPS next Q
-
EPS this Y
-95.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-36.85%
EPS Q/Q
42.45%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
440%
ROC
-1.84%
Gross Margin
-19%
Oper. Margin
-453%
Profit Margin
-276%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.012-5.67
52W High
-
52W Low
-
RSI
-
Rel Volume
0.32
Avg Volume
570.67K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.99375
-
-
Volatility
0.07%, 0.07%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
VTSAX
EMBASSY.NS
ABEC.DE
BRH.DE
BRYN.DE
Same Sector
603880.SS
GLMD
ORPH.IR
PBLA
FRISQ.ST
Check Those
CFX.TO
PIKK.ME
0661.HK
9070.T
1515.T
Similar Market Cap
CNET
ALAGR.PA
DN.TO
POS.L
P4O.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 570.67K
  • Market Capitalization 11.63M
  • Employee 93
  • CEO Mr. Yishai Zohar
  • Headquarters Boston,MA,US
  • IPO Date 2022-01-14
  • Website https://www.gelesis.com

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.